EUCTR2009-013935-39-FR进行中（未招募）1 期
The efficacy and safety of a daily oral administration of S06911 (strontium ranelate 2g/vitamin D3 1000 IU fixed combination) on vitamin D insufficiency in the treatment of osteoporotic postmenopausal women and men. A prospective, international phase III study with a 6-month double-blind period to assess the efficacy and safety of a daily oral administration of S06911 versus S12911 (strontium ranelate 2g) and a 6-month open-labelled extension for a subgroup of patients to assess safety of a daily oral administration of S06911.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Osteoporotic men and postmenopausal osteoporotic women
- •- Superior or equal to 50 year
- •- Caucasian
- •- Body mass index inferior to 30 kg/m2
- •- 25-OH vitamin D3 concentration > 22.5 nmol/L
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Progressive major illness, uncontrolled active disease, skeletal disease.
- •- History or increased risk of deep venous thrombosis or pulmonary embolism.
- •- History of intolerance, allergy or severe hypersensitivity with study drugs.
- •- History of alcohol abuse or drug dependance.
研究者
相似试验
进行中（未招募）
不适用
The efficacy and safety of a daily oral administration of S06911 (strontium ranelate 2g/vitamin D3 1000 IU fixed combination) on vitamin D insufficiency in the treatment of osteoporotic postmenopausal women and men. A prospective, international phase III study with a 6-month double-blind period to assess the efficacy and safety of a daily oral administration of S06911 versus S12911 (strontium ranelate 2g) and a 6-month open-labelled extension for a subgroup of patients to assess safety of a daily oral administration of S06911.Osteoporotic men and postmenauposal womenMedDRA version: 12.0Level: LLTClassification code 10031283Term: Osteoporosis fractureMedDRA version: 12.0Level: LLTClassification code 10031285Term: Osteoporosis postmenopausalEUCTR2009-013935-39-SKInstitut de Recherches Internationales Servier500
进行中（未招募）
不适用
Efficacy and safety of strontium ranelate/vitamin D3 combination on vitamin D insufficiency in the treatment of osteoporotic patient.Osteoporotic men and postmenauposal womenMedDRA version: 13.1Level: PTClassification code 10031285Term: Osteoporosis postmenopausalSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 13.1Level: LLTClassification code 10031283Term: Osteoporosis fractureSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2009-013935-39-BEInstitut de Recherches Internationales Servier500
进行中（未招募）
1 期
The efficacy and safety of a daily oral administration of S06911 (strontium ranelate 2g/vitamin D3 1000 IU fixed combination) on vitamin D insufficiency in the treatment of osteoporotic postmenopausal women and men. A prospective, international phase III study with a 6-month double-blind period to assess the efficacy and safety of a daily oral administration of S06911 versus S12911 (strontium ranelate 2g) and a 6-month open-labelled extension for a subgroup of patients to assess safety of a daily oral administration of S06911.Osteoporotic men and postmenauposal womenMedDRA version: 12.0 Level: LLT Classification code 10031283 Term: Osteoporosis fractureMedDRA version: 12.0 Level: LLT Classification code 10031285 Term: Osteoporosis postmenopausalEUCTR2009-013935-39-GBInstitut de Recherches Internationales Servier500
进行中（未招募）
不适用
The efficacy and safety of a daily oral administration of S06911 (strontium ranelate 2g/vitamin D3 1000 IU fixed combination) on vitamin D insufficiency in the treatment of osteoporotic postmenopausal women and men. A prospective, international phase III study with a 6-month double-blind period to assess the efficacy and safety of a daily oral administration of S06911 versus S12911 (strontium ranelate 2g) and a 6-month open-labelled extension for a subgroup of patients to assess safety of a daily oral administration of S06911.EUCTR2009-013935-39-HUInstitut de Recherches Internationales Servier500
进行中（未招募）
不适用
The efficacy and safety of a daily oral administration of S06911 (strontium ranelate 2g/vitamin D3 1000 IU fixed combination) on vitamin D deficiency in the treatment of osteoporotic postmenopausal women and men. A 12 month, prospective, open labelled, one treatment group international phase III study.Osteoporotic men and osteoporotic postmenauposal womenMedDRA version: 12.0Level: LLTClassification code 10031283Term: Osteoporosis fractureMedDRA version: 12.0Level: LLTClassification code 10031285Term: Osteoporosis postmenopausalEUCTR2009-014270-18-SKInstitut de Recherches Internationales Servier60